Skip to content

Predict future safety and
efficacy more efficiently

For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC-based drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas. By enabling our clients to get to crucial decision points faster and with higher confidence, we help them exclude non-valuable compounds and select the most promising candidates earlier.

Learn More
Proven, integrated drug discovery
services from Ncardia
 

By continually cultivating a special expertise in iPSC biology,
Ncardia has developed an integrated drug discovery platform
that primes your team for a higher probability for downstream
success that helps avoid costly attrition.   

It All Begins with a Mastery of Human Biology and iPSCs

There’s a kind of confidence that can only come with experience. At Ncardia, our clients have come to depend on us time and again for the strategic thinking and technical expertise that maximizes the potential of iPSCs to optimize their drug discovery. 

9 of 10 Top global pharma
companies served with
iPSC projects in 2020-21
60+ iPSC-based therapeutic
projects we’ve supported
since 2020
35 iPSC cell lines generated
from distinct sources
10+ Years of experience in
pursuing iPSC-based
innovations

 

Incorporate relevant cell models
in your drug discovery pipeline

As more and more drug discovery innovators look to capitalize on the unique value only iPSCs can deliver, they look to Ncardia as the uniquely qualified collaborator to join them on their all-important journeys. We’re ready to help make your next step the very best it can be. So let’s start with a conversation – about your vision, goals and expectations for your drug discovery projects.

Director Manufacturing Technology